Anthony Amato joins as Executive Vice President Business Development – Generics Division
Posted: October 7, 2021 at 5:00 a.m. MDT|Update: 26 minutes ago
MONMOUTH JUNCTION, NJ, October 7, 2021 / PRNewswire / – Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a strong portfolio of approved products and an advanced pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder and related conditions, today announced that Anthony Amato joined the company as Executive Vice President Business Development – Generics Division.
“With our continued growth and evolution into a larger and more complex operation, one of our priorities has been to bring a seasoned leader in pharmaceutical business development into the Tris team. We are delighted that Tony has joined Tris as Executive Vice President, Business Development. for our generics division. ”mentioned Ketan Mehta Tris’ Founder and Chairman and CEO. “Tony’s extensive experience growing specialty pharmaceutical companies through complex transactions and global collaborations, along with his goal-oriented leadership style, fits naturally into Tris’ culture and strategic plan. “
“I am honored and excited about this opportunity to join Tris, engage with potential partners and investors, and lead the business development efforts that will play a critical role in the future of Tris’ generic division. said Amato.
Tony’s expertise includes finding and executing valuable transactions, assessing market trends, developing successful partnerships, training and overseeing global cross-functional teams. His 20+ years of business development experience includes leadership roles in companies such as Hudson Healthcare Partners, Alvogen, Lupine Pharmaceuticals, Quadrant Capital Advisors, LLC and Barr Laboratories. Tony holds an MBA in Finance and Accounting from Zicklin School of Business, Baruch College, University of the City of New York and Juris Doctor from Touro Law School.
About Tris Pharma
Tris Pharma is a New Jerseyspecialty pharmaceutical company based on the development and commercialization of innovative drugs that meet the unmet needs of patients. Tris has used its innovative LiquiXR technology platform to develop its portfolio of differentiated solid and liquid drugs as well as a robust pipeline that spans multiple therapeutic categories, and its technology has formed the basis for many mutual value-added development partnerships. In United States, Tris promotes its portfolio of ADHD products (described at www.TrisADHD.com) using its pediatric and CNS-focused sales force. For more information, please visit www.trispharma.com.
Show original content:
SOURCE Tris Pharma, Inc.
The above press release has been provided courtesy of PRNewswire. The views, opinions and statements contained in the press release are not endorsed by Gray Media Group and do not necessarily state or reflect those of Gray Media Group, Inc.